Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumors

Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumors

Background MEDI9197 is an intratumorally administered toll-like receptor 7 and 8 agonist. In mice, MEDI9197 modulated antitumor immune responses, inhibited tumor growth and increased survival. This first-time-in-human, phase 1 study evaluated MEDI9197 with or without the programmed cell death ligand...

Full description

Saved in:
Bibliographic Details
Main Authors: Christopher Morehouse, Rakesh Kumar, Antoine Hollebecque, Aurélien Marabelle, Zachary A Cooper, Joshua Brody, Farzana Walcott, Charles Ferte, Shilpa Gupta, David S Hong, Lillian Siu, Antonio Jimeno, Pamela Munster, Juneko Grilley-Olson, Alain H Rook, Rebecca K S Wong, James W Welsh, Yuling Wu, Oday Hamid
Format: Article
Language:English
Published: BMJ Publishing Group 2020-10-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/8/2/e001095.full
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items